Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats.
It's product,NUZYRA® is an FDA-approved tetracycline-class antibiotic designed to address a significant unmet need for adult patients with CABP and ABSSSI caused by susceptible bacteria.
